2Seventy Bio's Data From Ongoing Phase 1 Plat-08 Trial Of SC-DARIC33 In Relapsed/Refractory Pediatric & Young Adult Acute Myeloid Leukemia Patients Show Rapamycin-Regulated In Vivo Expansion, Activation Of SC-DARIC33 T Cells, Concurrent Anti-CD33 Activity
Portfolio Pulse from Benzinga Newsdesk
2Seventy Bio's ongoing Phase 1 Plat-08 trial of SC-DARIC33 in relapsed/refractory pediatric and young adult acute myeloid leukemia patients shows rapamycin-regulated in vivo expansion, activation of SC-DARIC33 T cells, and concurrent anti-CD33 activity.
May 19, 2023 | 10:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
2Seventy Bio's positive Phase 1 trial results for SC-DARIC33 in pediatric and young adult leukemia patients may boost investor confidence in the company.
The positive results from the ongoing Phase 1 trial of SC-DARIC33 indicate that the treatment is showing promising outcomes in pediatric and young adult leukemia patients. This may lead to increased investor confidence in 2Seventy Bio, as the company's product pipeline shows potential for success. As a result, the stock price of TSVT may experience a short-term increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100